Viralytics Ltd., of Sydney, reported that a phase II study of Cavatak (coxsackievirus A21) in patients with late-stage melanoma was well tolerated by patients and provided both local and distant tumor responses. The company is presenting the data at the American Society of Clinical Oncology Annual Meeting in Chicago.